BioAge Labs, Inc.
BIOA
$4.51
-$0.10-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 89.51% | 19.18% | -- | -- | -- |
| Gross Profit | -66.48% | -3.62% | -- | -- | -- |
| SG&A Expenses | 52.96% | 94.39% | 74.64% | 41.01% | 14.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.03% | 39.68% | 86.54% | 150.33% | 13.85% |
| Operating Income | -62.23% | -28.35% | -86.54% | -150.33% | -13.85% |
| Income Before Tax | -58.77% | 0.49% | -0.82% | -60.05% | 20.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.77% | 0.49% | -0.82% | -60.05% | 20.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.77% | 0.49% | -0.82% | -60.05% | 20.98% |
| EBIT | -62.23% | -28.35% | -86.54% | -150.33% | -13.85% |
| EBITDA | -62.37% | -28.40% | -86.76% | -151.16% | -13.82% |
| EPS Basic | 92.42% | 95.36% | 95.32% | 23.39% | 22.75% |
| Normalized Basic EPS | 92.42% | 95.26% | 90.94% | 23.39% | 22.75% |
| EPS Diluted | 92.42% | 95.36% | 95.32% | 23.39% | 22.75% |
| Normalized Diluted EPS | 92.42% | 95.26% | 90.94% | 23.39% | 22.75% |
| Average Basic Shares Outstanding | 1,995.27% | 2,042.22% | 2,052.53% | 108.92% | 2.29% |
| Average Diluted Shares Outstanding | 1,995.27% | 2,042.22% | 2,052.53% | 108.92% | 2.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |